NewcelX Appoints World-Renowned Diabetes Cure-Focused Pioneer, Dr. Camillo Ricordi, to Scientific Advisory Board

New c elX’s appointment announcement is tied to a recently successful FDA Type B Pre-IND meeting for NCEL-101, which the company says provides a clear regulatory pathway toward clinical trials. The FDA feedback reduces early regulatory uncertainty for NCEL-101, a modest positive for the program’s near-term outlook.

Analysis

New c elX’s appointment announcement is tied to a recently successful FDA Type B Pre-IND meeting for NCEL-101, which the company says provides a clear regulatory pathway toward clinical trials. The FDA feedback reduces early regulatory uncertainty for NCEL-101, a modest positive for the program’s near-term outlook.